Doctors at the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance (SCCA) have performed more than 15,000 bone marrow transplants—more than any other institution in the world.
Contact us: Talk to a transplant doctor
Most experienced bone marrow transplant center
- Fred Hutch teams first developed clinical use of bone marrow transplants more than 40 years ago, under the direction of E. Donnall Thomas, MD, who won a Nobel Prize for his groundbreaking work.
- Even people who have not found a matched donor may receive treatment here using a cord blood transplant or a haploidentical transplant.
- We are advancing the use of transplants for a wider array of diseases — not only leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma, but also other cancers, bone marrow deficiencies, inborn errors of metabolism and immune disorders.
- Our experienced team supports you and your family, providing you with services and resources for your children and other members of your family.
- SCCA’s long-term follow-up care for transplant recipients is unmatched. Our highly trained transplant specialists provide lifelong support.
Ranked among the best transplant centers in the nation
- Ours is one of only 5 out of 179 transplant centers nationwide whose patients achieved higher-than-expected survival rates for the last four consecutive years, according to a study by the Center for International Blood and Marrow Transplant Research
- SCCA is the leading cancer treatment center in the region and among the top five nationally, according to U.S. News & World Report.
Access to the newest options and clinical trials
- We are a comprehensive cancer center, a designation from the National Cancer Institute that reflects our scientific leadership.
- Fred Hutch doctors and researchers offer well-developed clinical studies for people who need any type of transplant. We’ve pioneered advances such as:
- Less toxic, reduced-intensity transplants (non-myeloablative) for older people or those with multiple health problems
- Transplants using stem cells from cord blood or minimally mismatched or haploidentical sources so that nearly everyone has a donor
- Reduced post-transplant complications, like graft-versus-host disease, leading to better long-term survival